BR112016008158A2 - Moduladores de ror-gama-t de quinolinila ligados a metileno - Google Patents

Moduladores de ror-gama-t de quinolinila ligados a metileno

Info

Publication number
BR112016008158A2
BR112016008158A2 BR112016008158A BR112016008158A BR112016008158A2 BR 112016008158 A2 BR112016008158 A2 BR 112016008158A2 BR 112016008158 A BR112016008158 A BR 112016008158A BR 112016008158 A BR112016008158 A BR 112016008158A BR 112016008158 A2 BR112016008158 A2 BR 112016008158A2
Authority
BR
Brazil
Prior art keywords
ror
quinolinyl
modulators
methylene
gamma
Prior art date
Application number
BR112016008158A
Other languages
English (en)
Inventor
A Leonard Kristi
Barbay Kent
P Edwards James
D Kreutter Kevin
A Kummer David
Maharoof Umar
Nishimura Rachel
Urbanski Maud
Venkatesan Hariharan
Wang Aihua
L Wolin Ronald
R Woods Craig
Fourie Anne
Xue Xiaohua
D Cummings Maxwell
Moore Jones William
Goldberg Steven
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112016008158A2 publication Critical patent/BR112016008158A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MODULADORES DE ROR-GAMA-T DE QUINOLINILA LIGADOS A METILENO, SEUS USOS, COMPOSIÇÃO FARMACÊUTICA E SEU PROCESSO DE FABRICAÇÃO. Apresente invenção compreende compostos de Formula (I) FÓRMULA (I) Em que: R1, R2, R3, R4, R5, R6, R7, R8, e R9 são definidos no relatório descritivo. A invenção compreende, também, um método de tratamento ou melhora de uma síndrome, distúrbio ou doença, sendo que a dita síndrome, distúrbio ou doença é artrite reumatoide ou psoríase. A invenção também compreende um método para modular a atividade de ROR?t em um mamífero através da administração de uma quantidade terapeuticamente eficaz de pelo menos um composto de ao menos um composto, conforme definido na reivindicação 1.
BR112016008158A 2013-10-15 2013-10-15 Moduladores de ror-gama-t de quinolinila ligados a metileno BR112016008158A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/065048 WO2015057205A1 (en) 2013-10-15 2013-10-15 Methylene linked quinolinyl modulators of ror-gamma-t

Publications (1)

Publication Number Publication Date
BR112016008158A2 true BR112016008158A2 (pt) 2017-10-03

Family

ID=49551739

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016008158A BR112016008158A2 (pt) 2013-10-15 2013-10-15 Moduladores de ror-gama-t de quinolinila ligados a metileno

Country Status (10)

Country Link
EP (1) EP3057951B1 (pt)
JP (1) JP6346275B2 (pt)
KR (1) KR20160068957A (pt)
CN (1) CN105829294B (pt)
AU (2) AU2013403335B2 (pt)
BR (1) BR112016008158A2 (pt)
CA (1) CA2927153A1 (pt)
ES (1) ES2770676T3 (pt)
IL (1) IL245020B (pt)
WO (1) WO2015057205A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021219849A1 (en) 2020-04-30 2021-11-04 Idorsia Pharmaceuticals Ltd Azetidin-3-ylmethanol derivatives as ccr6 receptor modulators
WO2023057548A1 (en) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
CN118215662A (zh) 2021-10-26 2024-06-18 爱杜西亚药品有限公司 Ccr6受体调节剂
IL312369A (en) 2021-10-28 2024-06-01 Idorsia Pharmaceuticals Ltd CCR6 receptor modulators
AR129535A1 (es) 2022-06-21 2024-09-04 Syngenta Crop Prot Ag Derivados de carboxamida heterocíclicos bicíclicos microbiocidas
WO2024089191A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Microbiocidal heterobicyclic dihydrooxadiazine derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389739B1 (en) * 2006-10-05 2013-03-05 Orphagen Pharmaceuticals Modulators of retinoid-related orphan receptor gamma
EP2368886A1 (en) * 2010-03-01 2011-09-28 Phenex Pharmaceuticals AG Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease
WO2011112264A1 (en) * 2010-03-11 2011-09-15 New York University Compounds as rorϒt modulators and uses thereof
BR112013027670B1 (pt) * 2011-04-28 2021-11-09 Japan Tobacco Inc Composto de amida, composição farmacêutica e medicamento que o compreende e antagonista de rory
US9586928B2 (en) * 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
EP2800745B1 (en) * 2011-12-02 2020-02-12 Phenex Pharmaceuticals AG Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
CA2888210C (en) * 2012-10-16 2021-02-09 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t

Also Published As

Publication number Publication date
AU2019200726A1 (en) 2019-02-21
WO2015057205A1 (en) 2015-04-23
JP6346275B2 (ja) 2018-06-20
JP2016539918A (ja) 2016-12-22
CN105829294A (zh) 2016-08-03
CA2927153A1 (en) 2015-04-23
ES2770676T3 (es) 2020-07-02
AU2013403335A1 (en) 2016-04-28
IL245020B (en) 2019-09-26
AU2013403335B2 (en) 2018-11-15
CN105829294B (zh) 2018-11-09
IL245020A0 (en) 2016-05-31
EP3057951A1 (en) 2016-08-24
KR20160068957A (ko) 2016-06-15
EP3057951B1 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
BR112015008308A2 (pt) moduladores de quinolinila ligados por metileno do ror-gama-t
BR112016008258A2 (pt) moduladores de ror?t de quinolinila
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
BR112017027831A2 (pt) derivados de hidroxiácido, um processo para sua preparação e composições farmacêuticas contendo-os
BR112016008158A2 (pt) Moduladores de ror-gama-t de quinolinila ligados a metileno
GT201500092A (es) Moduladores de quinolinillo unidos a fenilo de ror-gamma-t
BR112018075433A2 (pt) derivados de piperidinila, processo para sua preparação e composições farmacêuticas contendo-os
BR112015027964A2 (pt) Compostos moduladores do regulador de condutância transmembrana da fibrose cística (cftr), composições farmacêuticas compreendendo os mesmos e uso destes para o tratamento da fibrose cística
BR112015008515A2 (pt) moduladores de ror t de quinolinila ligada à heteroarila
BR112017026132A2 (pt) piridinas substituídas e métodos de uso
BR112017008842A2 (pt) tiazóis como moduladores de ror?t
BR112014008045A2 (pt) benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
BR112015020772A2 (pt) compostos de pirimidina e piridina e seu uso
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
ECSP13012852A (es) Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a.
BR112013019714A2 (pt) azaindolilfenil sulfonamidas como inibidores de serina/treonina quinase
BR112017008816A2 (pt) álcoois trifluormetílicos como moduladores do roryt
CU24177B1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
BR112018071942A2 (pt) tiazóis de 6-aminopiridin-3-ila como moduladores de rorgamat
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
BRPI0924617A8 (pt) Compostos heterociclicos de fenoximetila
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112018001035A2 (pt) compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos
BR112016008215A2 (pt) moduladores de quinolinila ligados por alquila de roryt

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]